Document is current
Any future updates will be listed below
-
Authors
Gambichler, Thilo
Brune, Josefine
Rüth, Jonas
Abu Rached, Nessr
Boms, Stefanie
Weyer-Fahlbusch, Sera S.
Kreuter, Alexander
Hyun, Julia
Becker, Jürgen C.
Susok, Laura
-
Funding
Funding for this research was provided by:
Private Universität Witten/Herdecke gGmbH
- License Information
-
More Information
Article History
Received: 17 December 2025
Accepted: 6 January 2026
First Online: 25 February 2026
Declarations
:
: T.G. has received speakers and/or advisory board honoraria from BMS, Sanofi-Genzyme, MSD, Novartis Pharma, Roche, UCB, Abbvie, Almirall, Janssen, Lilly, Pfizer, Pierre Fabre, Merck-Serono, outside the submitted work. N.A. received funding, travel support and/or personal honoraria for lectures from Novartis Pharma, JanssenCilag GmbH, Recordati Rare Diseases Germany GmbH, UCB Pharma, Almirall Hermal GmbH, Bristol-Myers Squibb (BMS) and Johnson & Johnson that were independent of the work submitted. J.C.B is receiving speaker’s bureau honoraria from Amgen, Incyte Merck-Serono and Regeneron is a paid consultant/advisory board member for Merck-Serono, Incyte, 4SC and Regeneron. His group receives research grants from Regeneron, Merck Serono, and Alcedis. L.S. has received speakers and/or advisory board honoraria from UCB, BMS, Sun-Pharma, MSD, and Novartis. The other authors report no conflicts or competing interests.
: This study was conducted according to the declaration of Helsinki and followed a protocol approved by our institutional ethics review board (#16-5985).
